New stock news | Han Si Ai Tai delivers documents to the Hong Kong Stock Exchange.

According to the disclosure by the Hong Kong Stock Exchange on December 3, Hansaite BioMed (Wuhan) Co., Ltd. (referred to as Hansaite BioMed) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with Industrial and Commercial Bank International as its exclusive sponsor. The prospectus reveals that Hansaite BioMed is a biotechnology company with independent expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including a core product and nine other candidate products. It is reported that the core product, HX009, is a fusion protein of a self-developed anti-PD-1 (an immune checkpoint receptor)/SIRP dual functional antibody. During the reporting period and up to the last practicable date, the company has completed Phase I clinical trials of HX009 in Australia and China.